Home Metabolism UGT chemical Deferiprone

research use only

Deferiprone Iron-chelating Agent

Cat.No.S4067

Deferiprone (CP20) is a chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.
Deferiprone UGT chemical Chemical Structure

Chemical Structure

Molecular Weight: 139.15

Jump to

Quality Control

Batch: Purity: 99.97%
99.97

Solubility

In vitro
Batch:

Water : 27 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 139.15 Formula

C7H9NO2

 Storage (From the date of receipt)
CAS No. 30652-11-0 Download SDF Storage of Stock Solutions

Synonyms CP20 SMILES CC1=C(C(=O)C=CN1C)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Features
Possesses 10-fold higher cytotoxicity than maltol in both HL-60 and HSC-2 cell lines.
In vitro
Deferiprone (100 μM) is able to protect myocytes from doxorubicin-induced lactate dehydrogenase release. This compound (300 μM) quickly and efficiently removes iron(III) from its complex with doxorubicin. It (300 μM) rapidly enters myocytes and displaces iron from a fluorescence-quenched trapped intracellular iron-calcein complex, suggesting that in the myocyte, this compound should also be able to displace iron from its complex with doxorubicin. This chemical (3 mM) also greatly reduces hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. It (0.5 mM) increases removal of RBC membrane free iron in a time and dose dependent manner. This compound (0.3 mM) is effective in inhibiting radioactive iron mobilization from iron-loaded heart cells and protecting or restoring mitochondrial respiratory enzyme activity. It (1 mM) results in a sharp decrease in complex I-III activity in iron-loaded heart cells. This chemical shows cytotoxic effect of human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50 of 13.5 μg/mL, 9.9 μg/mL and 10.6 μg/mL, the cytotoxic activity of HK1 against HL-60 and HSC-2 cells is reduced in the presence of FeCl3. It (100 μg/mL) induces internucleosomal DNA fragmentation in HL-60 cells, but the addition of FeCl3 inhibits the DNA fragmentation. This compound (100 μg/mL) activates the caspase 3, 8 and 9 in HSC-2 cells.
In vivo
Deferiprone (100 mg/kg) reduces the mean basilar artery cross-sectional areas by 24% in rabbits. This compound combined with subarachnoid hemorrhage(SAH) shows a variable amount of corrugation of the internal elastic lamina in rabbits.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/15161023/
  • [5] https://pubmed.ncbi.nlm.nih.gov/9402590/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-08)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05604131 RECRUITING
Acute Myocardial Infarction Type 1
Rohan Dharmakumar
 2022-11-08 PHASE2
NCT07759895 NOT_YET_RECRUITING
Schizoaffecitve Disorder; Schizophrenia and Schizoaffective Disorder; Schizophrenia and Predominant Negative Symptoms
Amit Lotan
 2026-09-01 PHASE2
NCT03754725 ACTIVE_NOT_RECRUITING
SAH; Dementia
Duke University
 2020-10-01 PHASE1; PHASE2
NCT07023666 RECRUITING
Sickle Cell Disease
Inova Health Care Services
 2025-10-07 PHASE2
NCT05111821 TERMINATED
Stroke
University Hospital, Bordeaux
 2022-06-08 PHASE2
NCT00907283 UNKNOWN
Neurodegenerative Disease; Iron Overload
Ente Ospedaliero Ospedali Galliera
 2008-11 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.